129 related articles for article (PubMed ID: 8869897)
1. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus.
McGrath H; Martínez-Osuna P; Lee FA
Lupus; 1996 Aug; 5(4):269-74. PubMed ID: 8869897
[TBL] [Abstract][Full Text] [Related]
2. Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus.
McGrath H
Clin Exp Rheumatol; 1994; 12(2):129-35. PubMed ID: 8039279
[TBL] [Abstract][Full Text] [Related]
3. Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus.
Molina JF; McGrath H
J Rheumatol; 1997 Jun; 24(6):1072-4. PubMed ID: 9195511
[TBL] [Abstract][Full Text] [Related]
4. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
[TBL] [Abstract][Full Text] [Related]
5. Reversal of brain dysfunction with UV-A1 irradiation in a patient with systemic lupus.
Menon Y; McCarthy K; McGrath H
Lupus; 2003; 12(6):479-82. PubMed ID: 12873051
[TBL] [Abstract][Full Text] [Related]
6. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
7. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
8. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
9. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
Miyawaki S; Nishiyama S; Aita T; Yoshinaga Y
Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
[TBL] [Abstract][Full Text] [Related]
10. Elimination of anticardiolipin antibodies and cessation of cognitive decline in a UV-A1-irradiated systemic lupus erythematosus patient.
McGrath H
Lupus; 2005; 14(10):859-61. PubMed ID: 16304728
[TBL] [Abstract][Full Text] [Related]
11. Ultraviolet A1 (340-400 nm) irradiation and systemic lupus erythematosus.
McGrath H
J Investig Dermatol Symp Proc; 1999 Sep; 4(1):79-84. PubMed ID: 10537014
[TBL] [Abstract][Full Text] [Related]
12. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial.
Polderman MC; Huizinga TW; Le Cessie S; Pavel S
Ann Rheum Dis; 2001 Feb; 60(2):112-5. PubMed ID: 11156542
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus.
Polderman MC; le Cessie S; Huizinga TW; Pavel S
Rheumatology (Oxford); 2004 Nov; 43(11):1402-4. PubMed ID: 15304672
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
15. Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus.
McGrath H
Lupus; 2017 Oct; 26(12):1239-1251. PubMed ID: 28480786
[TBL] [Abstract][Full Text] [Related]
16. Ultraviolet irradiation in systemic lupus erythematosus: friend or foe?
Cohen MR; Isenberg DA
Br J Rheumatol; 1996 Oct; 35(10):1002-7. PubMed ID: 8883441
[TBL] [Abstract][Full Text] [Related]
17. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
19. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus.
Szegedi A; Simics E; Aleksza M; Horkay I; Gaál K; Sipka S; Hunyadi J; Kiss E
Rheumatology (Oxford); 2005 Jul; 44(7):925-31. PubMed ID: 15827034
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Dörner T; van Vollenhoven RF; Doria A; Jia B; Ross Terres JA; Silk ME; de Bono S; Fischer P; Wallace DJ
Arthritis Res Ther; 2022 May; 24(1):112. PubMed ID: 35578304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
